| HOME >> BIOLOGY >> TECHNOLOGY |
This press release contains forward-looking statements that reflect the
company's current views as to its products, development programs, science
and technology and business prospects. These forward-looking statements
involve risks and uncertainties, including but not limited to: (i) the
company's proprietary product candidates and those of certain of its
partners are in the early phases of clinical development and the risk of
failure is high and can occur at any stage prior to regulatory approval;
(ii) the company's or its partner's ability to obtain regulatory approval
for product candidates; (iii) the success of the company's partners in
sales and marketing efforts to generate from approved products and future
products (if any); and (iv) the company's patent applications for its
technology platforms and proprietary or partner product candidates may not
issue, patents that have issued may not be enforceable, or intellectual
property licenses from third parties may be required in the future.
Important risks and uncertainties are detailed in the company's reports and
other filings with the Securities and Exchange Commission, including its
most recent Quarterly Report on Form 10-Q filed on May 9, 2008. Actual
results could differ materially from the forward-looking statements
contained in this press release. The company undertakes no obligation to
update forward-looking statements, whether as a result of new information,
future events or otherwise.
Contacts:
Tim Warner (650) 283-4915 or twarner@nektar.com
Stephan Herrera (415) 488-7699 or sherrera@nektar.com
Jennifer Ruddock (650) 631-4954 or jruddock@nektar.com
| SOURCE Nektar Therapeutics Copyright©2008 PR Newswire. All rights reserved |